Monopar Therapeutics
Monopar Therapeutics is listed today as Monopar Therapeutics Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2015 | $2 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Monopar Therapeutics chose not to state its revenue in its newest notice of a funding round (Jun 2015).
SEC Form D · Jun 2015
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2015
That is all the official record says: Monopar Therapeutics has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Monopar Therapeutics are on record.
Investors#
No investor of Monopar Therapeutics is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 8 investors.
Largest shareholders today
Institutions holding Monopar Therapeutics Inc. shares, as of Sep 30, 2026.
- Janus Henderson Group Ltd.$89 M16.52%
- Ra Capital Management, L.P.$53 M9.85%
- BlackRock, Inc.$28 M5.15%
- Saturn V Capital Management LP$25 M4.61%
- Siren, L.L.C.$22 M3.99%
- State Street Corp$18 M3.39%
- Vanguard Capital Management LLC$17 M3.22%
- Polar Capital Holdings Plc$17 M3.16%
- Adage Capital Partners GP, L.L.C.$17 M3.09%
- TCG Crossover Management, LLC$16 M2.98%
- ADAR1 Capital Management, LLC$14 M2.64%
- Balyasny Asset Management L.P.$14 M2.61%
- Wellington Management Group LLP$14 M2.56%
- Deerfield Management Company, L.P.$11 M2.03%
- Candriam S.C.A.$10 M1.92%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew P. Mazar | Executive officer | Jun 2015 |
| Chandler D. Robinson | Executive officer | Jun 2015 |
| Christopher M. Starr | Executive officer | Jun 2015 |
| Andrew P. Mazar | Director | Jun 2015 |
| Chandler D. Robinson | Director | Jun 2015 |
| Christopher M. Starr | Director | Jun 2015 |
| Michael J. Brown | Director | Jun 2015 |
| Chandler D. Robinson | Promoter | Jun 2015 |
Went public since 2018. Its SEC number is that of a company listed on a stock exchange.